Eloquent solutions for the genetic age

Our proprietary research is centered around a novel drug delivery system that promotes osteogenesis while resolving the excess inflammation that often accompanies similar treatment modalities.

This research has the potential to change the lives of people living with rare bone diseases and cancers, including Osteogenesis Imperfecta (OI) and osteosarcoma, as well as common bone fractures and bone loss.  

The extreme biocompatibility of this delivery system allows it to be used for many diseases and disorders beyond the scope of bone regeneration including systemic inflammatory diseases and cancers. The slow, controlled release mechanism of this system will unlock the potential of existing and future drugs to be used where they would previously be cumbersome and ineffective.